{"id":66436,"date":"2026-05-27T12:59:46","date_gmt":"2026-05-27T04:59:46","guid":{"rendered":"https:\/\/flcube.com\/?p=66436"},"modified":"2026-05-27T12:59:47","modified_gmt":"2026-05-27T04:59:47","slug":"eli-lilly-to-acquire-three-infectious-disease-companies-for-up-to-3-83-billion-expanding-vaccine-portfolio-beyond-traditional-therapeutics","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=66436","title":{"rendered":"Eli Lilly to Acquire Three Infectious Disease Companies for Up to $3.83 Billion \u2013 Expanding Vaccine Portfolio Beyond Traditional Therapeutics"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\"><strong>Eli Lilly and Company<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/LLY:NYSE\">NYSE: LLY<\/a>) announced strategic agreements to acquire <strong>Curevo Inc.<\/strong>, <strong>LimmaTech Biologics AG<\/strong>, and <strong>Vaccine Company, Inc.<\/strong> in a combined transaction valued at up to <strong>$3.83 billion<\/strong>, significantly expanding the pharmaceutical giant&#8217;s research and development footprint into the infectious disease and vaccine space.<\/p>\n\n\n\n<h2 id=\"h-transaction-overview\" class=\"wp-block-heading\">Transaction Overview<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Target Company<\/th><th>Acquisition Value<\/th><th>Key Technology Focus<\/th><th>Development Stage<\/th><\/tr><\/thead><tbody><tr><td><strong>Curevo Inc.<\/strong><\/td><td>Up to $1.5 billion<\/td><td>Adjuvanted subunit vaccines<\/td><td>Phase 2 (shingles)<\/td><\/tr><tr><td><strong>LimmaTech Biologics AG<\/strong><\/td><td>Up to $780 million<\/td><td>Bacterial pathogen vaccines targeting toxins\/superantigens<\/td><td>Phase 1 (S. aureus)<\/td><\/tr><tr><td><strong>Vaccine Company, Inc.<\/strong><\/td><td>Up to $1.55 billion<\/td><td>In Vivo Nanoparticle (IVN) platform for viral pathogens<\/td><td>Preclinical\/Phase 1-ready (EBV)<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p class=\"wp-block-paragraph\">All transactions will be funded with cash and include upfront payments plus milestone-based subsequent payments tied to clinical, regulatory, and commercial achievements.<\/p>\n\n\n\n<h2 id=\"h-curevo-inc-shingles-vaccine-innovation\" class=\"wp-block-heading\">Curevo Inc. \u2013 Shingles Vaccine Innovation<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Lead Candidate:<\/strong> Amezosvatein \u2013 adjuvanted subunit vaccine for shingles prevention in adults<\/li>\n\n\n\n<li><strong>Technology:<\/strong> Next-generation synthetic adjuvant platform<\/li>\n\n\n\n<li><strong>Phase 2 Results:<\/strong> Matched immune response across all primary endpoints in head-to-head comparison against standard of care<\/li>\n\n\n\n<li><strong>Safety Profile:<\/strong> Reduced activity-limiting side effects by more than 50%, including:<\/li>\n\n\n\n<li>Fatigue<\/li>\n\n\n\n<li>Chills<\/li>\n\n\n\n<li>Injection site pain<\/li>\n\n\n\n<li><strong>Strategic Rationale:<\/strong> Addresses $2+ billion global shingles vaccine market with improved tolerability profile<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-limmatech-biologics-ag-combating-antimicrobial-resistance\" class=\"wp-block-heading\">LimmaTech Biologics AG \u2013 Combating Antimicrobial Resistance<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Focus:<\/strong> Vaccines against bacterial pathogens with rising antimicrobial resistance<\/li>\n\n\n\n<li><strong>Target Pathogens:<\/strong><\/li>\n\n\n\n<li><em>Staphylococcus aureus<\/em><\/li>\n\n\n\n<li><em>Neisseria gonorrhoeae<\/em><\/li>\n\n\n\n<li><em>Chlamydia trachomatis<\/em><\/li>\n\n\n\n<li><strong>Platform Innovation:<\/strong> Generates broad, durable immune responses by targeting disease-driving toxins and superantigens rather than whole bacteria<\/li>\n\n\n\n<li><strong>Lead Program:<\/strong> LTB-SA7 vaccine against <em>S. aureus<\/em> (Phase 1)<\/li>\n\n\n\n<li><strong>Market Opportunity:<\/strong> Addresses critical unmet need as traditional antibiotics lose efficacy against resistant strains<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-vaccine-company-inc-next-generation-viral-vaccine-platform\" class=\"wp-block-heading\">Vaccine Company, Inc. \u2013 Next-Generation Viral Vaccine Platform<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Core Technology:<\/strong> Proprietary <strong>In Vivo Nanoparticle (IVN)<\/strong> platform<\/li>\n\n\n\n<li><strong>Advantage:<\/strong> Enables antigen display that elicits durable immune responses comparable to virus-like particle (VLP) vaccines while avoiding complex VLP manufacturing processes<\/li>\n\n\n\n<li><strong>Pipeline:<\/strong> Broad preclinical portfolio spanning multiple viral pathogens<\/li>\n\n\n\n<li><strong>Lead Candidate:<\/strong> Five-antigen Epstein-Barr Virus (EBV) vaccine (Phase 1-ready)<\/li>\n\n\n\n<li><strong>Strategic Value:<\/strong> Provides scalable platform technology applicable across diverse viral indications<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-strategic-implications-amp-market-context\" class=\"wp-block-heading\">Strategic Implications &amp; Market Context<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Diversification Strategy:<\/strong> Lilly&#8217;s move represents a significant pivot beyond its core diabetes, obesity, and oncology franchises into preventive medicine<\/li>\n\n\n\n<li><strong>Competitive Landscape:<\/strong> Positions Lilly alongside established vaccine players (Pfizer, Moderna, GSK) while leveraging novel platform technologies<\/li>\n\n\n\n<li><strong>Financial Impact:<\/strong> Total potential consideration of $3.83 billion represents approximately 4% of Lilly&#8217;s current market capitalization<\/li>\n\n\n\n<li><strong>Integration Timeline:<\/strong> All three acquisitions expected to close in Q3 2026, subject to customary regulatory approvals and closing conditions<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Forward-Looking Statements<\/strong><br>This brief contains forward-looking statements regarding acquisition timelines, clinical development, and strategic expectations. Actual results may differ due to risks including regulatory approvals, integration challenges, clinical trial outcomes, and competitive dynamics.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Eli Lilly and Company (NYSE: LLY) announced strategic agreements to acquire Curevo Inc., LimmaTech Biologics&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10],"tags":[199,911,12],"class_list":["post-66436","post","type-post","status-publish","format-standard","hentry","category-company","category-deals","tag-eli-lilly","tag-nyse-lly","tag-vaccine"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v27.6) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Eli Lilly to Acquire Three Infectious Disease Companies for Up to $3.83 Billion \u2013 Expanding Vaccine Portfolio Beyond Traditional Therapeutics - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Eli Lilly and Company (NYSE: LLY) announced strategic agreements to acquire Curevo Inc., LimmaTech Biologics AG, and Vaccine Company, Inc. in a combined transaction valued at up to $3.83 billion, significantly expanding the pharmaceutical giant&#039;s research and development footprint into the infectious disease and vaccine space.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=66436\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Eli Lilly to Acquire Three Infectious Disease Companies for Up to $3.83 Billion \u2013 Expanding Vaccine Portfolio Beyond Traditional Therapeutics\" \/>\n<meta property=\"og:description\" content=\"Eli Lilly and Company (NYSE: LLY) announced strategic agreements to acquire Curevo Inc., LimmaTech Biologics AG, and Vaccine Company, Inc. in a combined transaction valued at up to $3.83 billion, significantly expanding the pharmaceutical giant&#039;s research and development footprint into the infectious disease and vaccine space.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=66436\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-05-27T04:59:46+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-05-27T04:59:47+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=66436#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=66436\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Eli Lilly to Acquire Three Infectious Disease Companies for Up to $3.83 Billion \u2013 Expanding Vaccine Portfolio Beyond Traditional Therapeutics\",\"datePublished\":\"2026-05-27T04:59:46+00:00\",\"dateModified\":\"2026-05-27T04:59:47+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=66436\"},\"wordCount\":441,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Eli Lilly\",\"NYSE: LLY\",\"Vaccine\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=66436#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=66436\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=66436\",\"name\":\"Eli Lilly to Acquire Three Infectious Disease Companies for Up to $3.83 Billion \u2013 Expanding Vaccine Portfolio Beyond Traditional Therapeutics - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-05-27T04:59:46+00:00\",\"dateModified\":\"2026-05-27T04:59:47+00:00\",\"description\":\"Eli Lilly and Company (NYSE: LLY) announced strategic agreements to acquire Curevo Inc., LimmaTech Biologics AG, and Vaccine Company, Inc. in a combined transaction valued at up to $3.83 billion, significantly expanding the pharmaceutical giant's research and development footprint into the infectious disease and vaccine space.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=66436#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=66436\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=66436#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Eli Lilly to Acquire Three Infectious Disease Companies for Up to $3.83 Billion \u2013 Expanding Vaccine Portfolio Beyond Traditional Therapeutics\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Eli Lilly to Acquire Three Infectious Disease Companies for Up to $3.83 Billion \u2013 Expanding Vaccine Portfolio Beyond Traditional Therapeutics - Insight, China&#039;s Pharmaceutical Industry","description":"Eli Lilly and Company (NYSE: LLY) announced strategic agreements to acquire Curevo Inc., LimmaTech Biologics AG, and Vaccine Company, Inc. in a combined transaction valued at up to $3.83 billion, significantly expanding the pharmaceutical giant's research and development footprint into the infectious disease and vaccine space.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=66436","og_locale":"en_US","og_type":"article","og_title":"Eli Lilly to Acquire Three Infectious Disease Companies for Up to $3.83 Billion \u2013 Expanding Vaccine Portfolio Beyond Traditional Therapeutics","og_description":"Eli Lilly and Company (NYSE: LLY) announced strategic agreements to acquire Curevo Inc., LimmaTech Biologics AG, and Vaccine Company, Inc. in a combined transaction valued at up to $3.83 billion, significantly expanding the pharmaceutical giant's research and development footprint into the infectious disease and vaccine space.","og_url":"https:\/\/flcube.com\/?p=66436","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-05-27T04:59:46+00:00","article_modified_time":"2026-05-27T04:59:47+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=66436#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=66436"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Eli Lilly to Acquire Three Infectious Disease Companies for Up to $3.83 Billion \u2013 Expanding Vaccine Portfolio Beyond Traditional Therapeutics","datePublished":"2026-05-27T04:59:46+00:00","dateModified":"2026-05-27T04:59:47+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=66436"},"wordCount":441,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Eli Lilly","NYSE: LLY","Vaccine"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=66436#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=66436","url":"https:\/\/flcube.com\/?p=66436","name":"Eli Lilly to Acquire Three Infectious Disease Companies for Up to $3.83 Billion \u2013 Expanding Vaccine Portfolio Beyond Traditional Therapeutics - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-05-27T04:59:46+00:00","dateModified":"2026-05-27T04:59:47+00:00","description":"Eli Lilly and Company (NYSE: LLY) announced strategic agreements to acquire Curevo Inc., LimmaTech Biologics AG, and Vaccine Company, Inc. in a combined transaction valued at up to $3.83 billion, significantly expanding the pharmaceutical giant's research and development footprint into the infectious disease and vaccine space.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=66436#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=66436"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=66436#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Eli Lilly to Acquire Three Infectious Disease Companies for Up to $3.83 Billion \u2013 Expanding Vaccine Portfolio Beyond Traditional Therapeutics"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/66436","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=66436"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/66436\/revisions"}],"predecessor-version":[{"id":66437,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/66436\/revisions\/66437"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=66436"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=66436"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=66436"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}